Pfizer fight with Starboard heats up, hedge fund alleges executive pressure
New throughout with details on campaign, letter, meeting, stock price, Pfizer history
By Svea Herbst-Bayliss and Michael Erman
Oct 10 (Reuters) -The corporate clash between Pfizer PFE.N and Starboard Value heated up on Thursday when the activist investment firm pressed the U.S. drugmaker to investigate actions by its board, after two former executives backed out of its campaign against the company.
Jeffrey Smith, who runs Starboard, pushed Pfizer's board on Thursday to set up a special committee to probe potential "coercive conduct" that may have promptedthe two executives who had planned on working with the hedge fund to change their minds.
Starboard built a roughly $1-billionposition in the company, which has a $167-billion market capitalization, and said former chief executive Ian Read and former chief financial officer Frank D'Amelio were concerned about the company's path and offered their assistance.
Starboard alleged the former executives reversed course because people within Pfizer or their representatives contacted Read and D'Amelio and "purportedly threatened to commence costly litigation against them."
In a letter to the Pfizer board, Smith wrotehe has been told of recent events that put Read and D'Amelio under pressure.If they did not publicly support Pfizer CEO Albert Bourla they could risk having previous compensation clawed back and the cancellation of unvested performance stock units, the letter said.
Hours earlier, Guggenheim Securities, Pfizer's longtime banker,said Read and D'Amelio "decided not to be involved in the efforts of Starboard regarding Pfizer" adding that they fully support Bourla.
Pfizer did not immediately respond to a request for comment.
The dueling statements signal a widening gulf between the two sides before they have had their first meeting, which is scheduled for next Wednesday.
Lawyers and bankers said hedge funds often rely on help from other large investors during their campaigns but that pulling in former executives so publicly and so early was unusual.
Smith said in his letter he hopes to have "constructive engagement" with Pfizer.
Starboard has not provided details of what it wants Pfizer to do, noting only that the company's share price has dropped dramatically since 2019 when Bourla took over as CEO as Read's hand-picked successor. Over the last 52 weeks, the stock price has dropped 11% but it has climbed 4% in the last five days to trade at $29.60.
The hedge fund also pointed to Pfizer spending $70 billion on mergers, which has been criticized by some Wall Street analysts as problematic.
Pfizer is best known for its COVID-19 vaccine and before that, erectile-dysfunctiondrug Viagra and cholesterol-loweringdrug Lipitor.
With lower demand for the vaccine after the pandemic, Pfizer's stock price has suffered. The company's stock is currently trading at about half its pandemic-era high.
The company has also contended withdisappointing data for an experimental obesity drug, theweak launch of its respiratory syncytial virus vaccine, andpulling its sickle-cell-disease treatment Oxbryta due to deaths in clinical trials.
Starboard has previously waged campaigns against healthcare companies, including unsuccessfully trying to scuttle Bristol-Myers Squibb's BMY.N bid to buy Celgene in 2019.
Reporting by Svea Herbst-Bayliss and Michael Erman in New York with additional reporting by Bhanvi Satija in Bengaluru and ; Editing by Anil D'Silva and Rod Nickel
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
